AGAlessandra Galdiero

Alessandra Galdiero

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alessandra Galdiero has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Integrated Molecular and Cytogenomic Characterization of Acute Myeloid Leukaemia Reveals Hidden Clonal Architecture and Refines ELN Risk Stratification

    by Alessandra Galdiero, Alessandra Potenza, Aurora Siniscalchi, Cosimo Barbato, Roberta Visconti, Santa Errichiello, Mariangela Capone, Fabrizio Quarantelli, Giuliano Pennacchio, Angelo Zanniti, et al.

    Acute myeloid leukaemia (AML) is a genetically heterogeneous haematologic malignancy driven by the stepwise acquisition of chromosomal abnormalities and somatic mutations, resulting in clonal evolution. Current guidelines recommend integrating morphology, immunophenotyping, cytogenetics, and molecular analyses for disease classification and prognostic stratification. However, discrepancies between conventional cytogenetics and genome-wide approaches may occur. We describe a 70-year-old man presenting with severe pancytopenia, diagnosed with AML based on bone marrow morphology and immunophenotyping. Karyotyping revealed a deletion of chromosome 11 and additional material on chromosome 12. Targeted Next-Generation Sequencing identified pathogenic variants in FLT3, SF3B1, and EZH2, together with copy number losses involving chromosomes 7 and 11, the former not detected by chromosome banding analysis. To resolve this discrepancy, genome-wide Array-CGH+SNP analysis confirmed monosomy 7 and uncovered additional genomic abnormalities. Fluorescence in situ hybridization (FISH) validated chromosome 7 loss at the single-cell level. Taken together, these findings suggest that monosomy 7 was restricted to a leukaemic subclone underrepresented in metaphase analysis, likely owing to differential proliferative capacity among leukaemic populations. This case highlights how integrated cytogenomic profiling can uncover clinically relevant clonal heterogeneity missed by conventional cytogenetics alone, refining ELN risk stratification and underscoring the value of combining chromosome-based and DNA-based technologies in AML.

  • Open Access

    Subclones with variants of uncertain clinical significance might contribute to ineffective hemopoiesis and leukemia predisposition

    by Valentina Giudice, Bianca Serio, Santa Errichiello, Idalucia Ferrara, Alessandra Galdiero, Angela Bertolini, Roberta Visconti, Danilo De Novellis, Roberto Guariglia, Serena Luponio, et al.

    Background: Splicing modifications, genomic instability, and hypomethylation are central mechanisms promoting myelodysplasia and acute myeloid leukemia (AML). In this real‐life retrospective study, to elucidate pathophysiology of clonal hemopoiesis in hematological malignancies, we investigated clinical significance of mutations in leukemia‐related genes of known pathogenetic significance and of variants of uncertain clinical significance (VUS) in a cohort of patients with MDS and AML.Methods: A total of 59 consecutive subjects diagnosed with MDS, 48 with AML, and 17 with clonal cytopenia with unknown significance were screened for somatic mutations in AML‐related genes by next‐generation sequencing.Results: We showed that TET2, SETBP1, ASXL1, EZH2, RUNX1, SRSF2, DNMT3A, and IDH1/2 were commonly mutated. MDS patients also showed a high genetic complexity, especially for SETBP1. Moreover, the presence of SETBP1 wild‐type or two or more simultaneous VUS variants identified a subgroup of AML and MDS patients with better outcome, while the presence of single SETBP1 VUS variant was related to a worse prognosis, regardless TET2 mutational status.Conclusions: In conclusions, we linked both pathogenic and VUS variants in AML‐related genes to clonal hematopoiesis; therefore, we proposed to consider those variants as prognostic markers in leukemia and myelodysplasia. However, further studies in larger prospective cohorts are required to validate our results.